{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"1.9","value":"1.9"},{"groupId":"OG001","lowerLimit":"3.7","upperLimit":"6.0","value":"4.7"},{"groupId":"OG002","lowerLimit":"3.5","upperLimit":"5.4","value":"3.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"188"},{"groupId":"OG002","value":"190"}],"units":"Participants"}],"description":"PFS is defined as the time from date of randomization to the date of the first documentation of PD or death due to any cause, whichever occurs first. PFS time was summarized by treatment arm using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Avelumab 10 milligram (mg)/kilogram (kg) given as a 1-hour intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles.","id":"OG000","title":"Avelumab"},{"description":"Avelumab 10 mg/kg given as a 1-hour IV Q2W in 4-week cycles + pegylated liposomal doxorubicin (PLD) 40 mg/square meter given as a 1-hour IV infusion every 4 weeks (Q4W) in 4-week cycles.","id":"OG001","title":"Avelumab + PLD"},{"description":"PLD 40 mg/square meter given as a 1-hour IV infusion Q4W in 4-week cycles.","id":"OG002","title":"Pegylated Liposomal Doxorubicin (PLD)"}],"paramType":"MEDIAN","populationDescription":"The secondary efficacy endpoint was analyzed in FAS. The FAS included all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"From randomization to date of first documentation of PD or death due to any cause whichever was first (up to 30 months); based on cutoff date: 19 September 2018.","title":"PFS Based on Investigator Assessment According to RECIST Version 1.1","type":"SECONDARY","unitOfMeasure":"month"}